{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:44:10Z","timestamp":1792003450269,"version":"4.4.0"},"reference-count":53,"publisher":"Georg Thieme Verlag KG","issue":"01","funder":[{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"crossref","award":["202134-30-31"],"award-info":[{"award-number":["202134-30-31"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During the 2023\/24 season, nirsevimab significantly reduced the risk of bronchiolitis and confirmed respiratory syncytial virus (RSV) infections in primary care, hospital, and pediatric intensive care unit admissions among infants aged 0 to 11 months, even in a season with a high community RSV burden, particularly for older infants. These findings are very useful for public health authorities to continue to implement immunization campaigns against RSV in the coming seasons. Moreover, universal immunization against RSV represents a transformative step toward reducing the burden of RSV in infants. With promising evidence from recently published studies, the expectations for a reduction of RSV-associated hospitalizations, alongside the improvement of public health outcomes and equitable access to these measures, are high. However, achieving these goals will require addressing challenges related to vaccine uptake, funding, and RSV surveillance to prompt detect resistances due to mutations of the virus. These interventions need to be integrated into public health strategies because they hold the potential to make a significant impact on infant's health worldwide.<\/jats:p>","DOI":"10.1055\/a-2531-0968","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:06:01Z","timestamp":1738627561000},"page":"031-040","source":"Crossref","is-referenced-by-count":2,"title":["Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations"],"prefix":"10.1055","volume":"46","author":[{"given":"Antoni","family":"Soriano-Arandes","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"},{"name":"Infection and Immunity in Pediatric Patients, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Creus-Costa","sequence":"additional","affiliation":[{"name":"Infection and Immunity in Pediatric Patients, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"},{"name":"Pediatric Hospitalization Unit, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Perramon-Malavez","sequence":"additional","affiliation":[{"name":"Department of Physics, Computational Biology and Complex Systems (BIOCOM-SC) Group, Universitat Polit\u00e8cnica de Catalunya, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Respiratory Viruses Unit, Microbiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red de Enfermedades Infecciosas CIBERINFEC, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgina","family":"Vila","sequence":"additional","affiliation":[{"name":"Infection and Immunity in Pediatric Patients, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"},{"name":"Pediatric Hospitalization Unit, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gatell","sequence":"additional","affiliation":[{"name":"Equip Territorial d'Atenci\u00f3 Prim\u00e0ria del Garraf, Institut Catal\u00e0 de la Salut, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pi\u00f1ana","sequence":"additional","affiliation":[{"name":"Respiratory Viruses Unit, Microbiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red de Enfermedades Infecciosas CIBERINFEC, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pepe","family":"Serrano","sequence":"additional","affiliation":[{"name":"Societat Catalana de Pediatria, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gonz\u00e1lez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Respiratory Viruses Unit, Microbiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red de Enfermedades Infecciosas CIBERINFEC, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Capdevila","sequence":"additional","affiliation":[{"name":"ABS Les Borges Blanques, Institut Catal\u00e0 de la Salut, Lleida, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Prats","sequence":"additional","affiliation":[{"name":"Department of Physics, Computational Biology and Complex Systems (BIOCOM-SC) Group, Universitat Polit\u00e8cnica de Catalunya, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Soler-Palacin","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"},{"name":"Infection and Immunity in Pediatric Patients, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Ant\u00f3n","sequence":"additional","affiliation":[{"name":"Respiratory Viruses Unit, Microbiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red de Enfermedades Infecciosas CIBERINFEC, Instituto Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/jpc.16197","article-title":"Respiratory syncytial virus, recurrent wheeze and asthma: a narrative review of pathophysiology, prevention and future directions","volume":"58","author":"E Binns","year":"2022","journal-title":"J Paediatr Child Health"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"e13085","DOI":"10.1111\/irv.13085","article-title":"The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): a long-term, clinical, epidemiologic and economic study","volume":"17","author":"J Vila","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: infection, detection, and new options for prevention and treatment","volume":"30","author":"C Griffiths","year":"2017","journal-title":"Clin Microbiol Rev"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/pai.13131","article-title":"Risk of childhood wheeze and asthma after respiratory syncytial virus infection in full-term infants","volume":"31","author":"A Mejias","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"issue":"S 01","key":"ref5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40121-020-00387-2","article-title":"Current state of respiratory syncytial virus disease and management","volume":"10","author":"A Chatterjee","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"e20193611","DOI":"10.1542\/peds.2019-3611","article-title":"Respiratory syncytial virus-associated hospitalizations among young children: 2015-2016","volume":"146","author":"B Rha","year":"2020","journal-title":"Pediatrics"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Y Li","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/infdis\/jiad188","article-title":"Burden of respiratory syncytial virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years","volume":"228","author":"M Del Riccio","year":"2023","journal-title":"J Infect Dis"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"e2023062574","DOI":"10.1542\/peds.2023-062574","article-title":"Respiratory syncytial virus-associated hospitalizations among children <5 years old: 2016 to 2020","volume":"153","author":"A T Curns","year":"2024","journal-title":"Pediatrics"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamapediatrics.2023.5734","article-title":"Outcomes of pediatric SARS-CoV-2 omicron infection vs influenza and respiratory syncytial virus infections","volume":"178","author":"P Hedberg","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"S 01","key":"ref12","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/infdis\/jiac141","article-title":"A retrospective cohort study on infant respiratory tract infection hospitalizations and recurrent wheeze and asthma risk: impact of respiratory syncytial virus","volume":"226","author":"M van Wijhe","year":"2022","journal-title":"J Infect Dis"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/infdis\/jiad189","article-title":"Estimation of the number of respiratory syncytial virus-associated hospitalizations in adults in the European Union","volume":"228","author":"R Osei-Yeboah","year":"2023","journal-title":"J Infect Dis"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"e14131","DOI":"10.1111\/pai.14131","article-title":"Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: a Spanish 6-year population-based longitudinal study","volume":"35","author":"S Ares-G\u00f3mez","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/s12879-022-07745-0","article-title":"Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study","volume":"22","author":"F Martin\u00f3n-Torres","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"2231818","DOI":"10.1080\/21645515.2023.2231818","article-title":"Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021","volume":"19","author":"E Gea-Izquierdo","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","article-title":"Respiratory syncytial virus\u2013a comprehensive review","volume":"45","author":"A T Borchers","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/irv.12715","article-title":"Toward unified molecular surveillance of RSV: a proposal for genotype definition","volume":"14","author":"S Goya","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"106153","DOI":"10.1016\/j.jinf.2024.106153","article-title":"Genomic evolution of human respiratory syncytial virus during a decade (2013-2023): bridging the path to monoclonal antibody surveillance","volume":"88","author":"M Pi\u00f1ana","year":"2024","journal-title":"J Infect"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e1107","DOI":"10.1055\/a-1990-2633","article-title":"Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: a systematic review","volume":"41","author":"T Gonzales","year":"2024","journal-title":"Am J Perinatol"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"M P Griffin","year":"2020","journal-title":"N Engl J Med"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"L L Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"ref24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants","volume":"388","author":"W J Muller","year":"2023","journal-title":"N Engl J Med"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMc2112186","article-title":"Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity","volume":"386","author":"J Domachowske","year":"2022","journal-title":"N Engl J Med"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41591-024-03006-6","article-title":"Author correction: durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants","volume":"30","author":"D Wilkins","year":"2024","journal-title":"Nat Med"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jpids\/piad113","article-title":"Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season","volume":"13","author":"R Dagan","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00570-X","article-title":"Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study","author":"S Fourati","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"26","key":"ref29","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"S B Drysdale","year":"2023","journal-title":"N Engl J Med"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"A Tang","year":"2019","journal-title":"Nat Commun"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0022-3476(81)80829-3","article-title":"Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level","volume":"98","author":"W P Glezen","year":"1981","journal-title":"J Pediatr"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/infdis\/jiab315","article-title":"Respiratory syncytial virus (RSV)-specific antibodies in pregnant women and subsequent risk of RSV hospitalization in young infants","volume":"225","author":"K Koivisto","year":"2022","journal-title":"J Infect Dis"},{"issue":"32","key":"ref33","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.vaccine.2022.06.034","article-title":"Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries","volume":"40","author":"J E Atwell","year":"2022","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.12688\/wellcomeopenres.17636.2","article-title":"Efficiency of transplacental transfer of respiratory syncytial virus (RSV) specific antibodies among pregnant women in Kenya","volume":"7","author":"J U Nyiro","year":"2022","journal-title":"Wellcome Open Res"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jpids\/piaa040","article-title":"Transplacental respiratory syncytial virus and influenza virus antibody transfer in Alaska native and Seattle mother-infant pairs","volume":"10","author":"H Y Chu","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/infdis\/jiu316","article-title":"Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh","volume":"210","author":"H Y Chu","year":"2014","journal-title":"J Infect Dis"},{"issue":"16","key":"ref38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"B Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"34","key":"ref42","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices - United States, 2023","volume":"72","author":"J M Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"09","key":"ref45","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/archdischild-2024-327153","article-title":"Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)","volume":"109","author":"E Coma","year":"2024","journal-title":"Arch Dis Child"},{"issue":"12","key":"ref46","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1007\/s00431-024-05779-x","article-title":"Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023\/2024 season","volume":"183","author":"A Perramon-Malavez","year":"2024","journal-title":"Eur J Pediatr"},{"issue":"06","key":"ref47","doi-asserted-by":"crossref","first-page":"2400046","DOI":"10.2807\/1560-7917.ES.2024.29.6.2400046","article-title":"Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024","volume":"29","author":"M L\u00f3pez-Lacort","year":"2024","journal-title":"Euro Surveill"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/vaccines12040383","article-title":"Effectiveness of nirsevimab immunoprophylaxis administered at birth to prevent infant hospitalisation for respiratory syncytial virus infection: a population-based cohort study","volume":"12","author":"G Ezpeleta","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"08","key":"ref49","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"S Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"ref50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2352-4642(24)00143-3","article-title":"Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study","volume":"8","author":"A Brault","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"e13311","DOI":"10.1111\/irv.13311","article-title":"Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in paediatric intensive care units in France, September 2023-January 2024","volume":"18","author":"J Paireau","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - new vaccine surveillance network, October 2023-February 2024","volume":"73","author":"H L Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"2400033","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033","article-title":"Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023\/24 season in Luxembourg","volume":"29","author":"C Ernst","year":"2024","journal-title":"Euro Surveill"},{"issue":"05","key":"ref58","doi-asserted-by":"crossref","first-page":"e13294","DOI":"10.1111\/irv.13294","article-title":"Estimated impact of nirsevimab on the incidence of respiratory syncytial virus infections requiring hospital admission in children <\u20091\u2009year, weeks 40, 2023, to 8, 2024, Spain","volume":"18","author":"C Mazagatos","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"ref59","first-page":"100629","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: a simulation study","volume":"28","author":"A Shoukat","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pedneo.2023.04.015","article-title":"Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6\/7 weeks' gestation in the United States","volume":"65","author":"T Yu","year":"2024","journal-title":"Pediatr Neonatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S0140-6736(23)02368-1","article-title":"GBD 2019 child and adolescent communicable disease collaborators. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990\u20132019: a systematic analysis of the global burden of disease study 2019","volume":"402","year":"2023","journal-title":"Lancet"},{"issue":"02","key":"ref62","doi-asserted-by":"crossref","first-page":"e29453","DOI":"10.1002\/jmv.29453","article-title":"Respiratory syncytial virus immunoprophylaxis: novel opportunities and a call for equity","volume":"96","author":"P Rzymski","year":"2024","journal-title":"J Med Virol"},{"issue":"08","key":"ref63","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1097\/INF.0000000000004354","article-title":"Prevention of RSV bronchiolitis: an ethical issue","volume":"43","author":"A Villani","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"49","key":"ref64","doi-asserted-by":"crossref","first-page":"2300606","DOI":"10.2807\/1560-7917.ES.2023.28.49.2300606","article-title":"Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023","volume":"28","author":"F Martin\u00f3n-Torres","year":"2023","journal-title":"Euro Surveill"},{"issue":"09","key":"ref65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.arbres.2023.06.006","article-title":"The path towards effective respiratory syncytial virus immunization policies: recommended actions","volume":"59","author":"F Martin\u00f3n-Torres","year":"2023","journal-title":"Arch Bronconeumol"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2531-0968.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T22:50:09Z","timestamp":1749250209000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2531-0968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":53,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,6,6]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2531-0968","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,3]]},"published":{"date-parts":[[2025,2]]}}}